| Document |
Document Title |
|
WO/2024/149150A1 |
Provided in the present invention are a deuterated pyrazolopyrimidine derivative, and a preparation method therefor, a pharmaceutical composition thereof, a conjugate thereof and the use thereof, which belong to the technical field of me...
|
|
WO/2024/151786A1 |
Dried blood spots (DBS) collected on a substrate material are used in the quantitation of amino acids, acylcamitines, organic acids and numerous other small molecules. One of their main application areas is newborn screening. In order to...
|
|
WO/2024/145422A1 |
The present disclosure relates to a process for making a compound of the formula I and to the enantioselective synthesis to prepare the S or R isomers. It also relates to intermediates in the process.
|
|
WO/2024/131935A1 |
The present invention belongs to the technical field of medicine, and in particular relates to a novel aromatic ring derivative containing an amide substitution or a pharmaceutically acceptable salt thereof. The diseases comprise, but ar...
|
|
WO/2024/133048A1 |
The present invention relates to a method for preparing deuterated compounds and to deuterated compounds produced by the same method.
|
|
WO/2024/125651A1 |
The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a compound of formula I or a tautomer thereof, a cis-trans isomer thereof or a pharmaceutically acceptable salt thereof, and use thereof...
|
|
WO/2024/125346A1 |
The present invention relates to preparation of a deuterated 4-phenylpiperidine-4-ol compound and use thereof. The compound has a structural general formula of formula (I) or formula (II). Also disclosed are preparation of the compound a...
|
|
WO/2024/129763A1 |
Provided herein are inhibitors of TNF-α, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-α inhibitory compounds for the treatment of diseases or disorders.
|
|
WO/2024/130105A1 |
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g., evaluating the biodistribution and/or concentration of a biomolecule in a subject.
|
|
WO/2024/120557A1 |
The present invention relates to the use of cyclen based compound of general formula (I) wherein R is NO2 or F; A is independently selected from -CH2COOH; -CH(CH3)COOH;; -CH((CH2)nCH3)COOH, wherein n is an integer in the range of from 1 ...
|
|
WO/2024/109676A1 |
Provided is a pyrazolopyrimidine derivative having a Bruton's tyrosine kinase (BTK) inhibitory effect. The pyrazolopyrimidine derivative is a deuterated compound, and a pharmaceutically acceptable salt, a hydrate or a solvate. Also provi...
|
|
WO/2024/109789A1 |
The present invention relates to a picolinamide compound as a Bruton's tyrosine kinase (BTK) inhibitor. Specifically, disclosed in the present invention are a 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-4-yl]pyridi
ne-3-carboxamide ...
|
|
WO/2024/094731A1 |
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormalit...
|
|
WO/2024/094607A1 |
The present invention generally relates to the field of isotope labeled and non-labeled gentamicin congeners and synthetic methods for the preparation of such congeners. In particular, the present invention relates to isotope labeled gen...
|
|
WO/2024/077059A1 |
Described herein are crystalline forms of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy-d2)-3'-flu
oro-2'-(3-(2-hydroxypropan-2-yl)-1H-pyrazol-1-yl)-5',6-dimet
hyl-2H-[1,4'-bipyridin]-2-one (compound 1), or a pharmaceutically accepta...
|
|
WO/2024/074813A1 |
The invention relates to a compound of the formula Xm-(Y-L-T)n and a method for the detection or prognosis of a disease in the exhaled breath of a subject. X, when present is a moiety operable to target the compound to a site of interest...
|
|
WO/2024/066981A1 |
Provided in the present invention are deuterated pyrazole derivatives, of which the structures are represented as formula (I). Further disclosed in the present invention are pharmaceutically acceptable salts and stereoisomers of the deri...
|
|
WO/2024/067503A1 |
The present application provides a composition and an organic electroluminescent device comprising same. The composition comprises two compounds represented by formula I and a compound represented by formula II; or the composition compri...
|
|
WO/2024/060356A1 |
The present invention relates to an economical and feasible method for industrially producing a deuterated COVID-19 medicament key intermediate D. The method has low reaction line cost, and high conversion rate, selectivity, reaction yie...
|
|
WO/2024/063095A1 |
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely man...
|
|
WO/2024/064968A1 |
The present disclosure relates to the field of fibroblast activation protein (FAP) inhibitors, conjugates comprising the novel FAP inhibitors, including radiotracers, for the imaging, diagnosis and treatment of conditions characterized b...
|
|
WO/2024/057212A1 |
The present disclosure describes hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications. The present disclosure describes methods for producing hyperpolarized materials for use...
|
|
WO/2024/059608A1 |
Provided herein is a deuterated compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R15a, R15b, R16a, R16b, R17, R18, R19, R21a,...
|
|
WO/2024/058665A1 |
The invention relates to the field of medicinal chemistry and radiopharmaceuticals, in particular to means, methods and cassettes for the automated synthesis of the radiotracer 6-L-[18F]fluoro-3,4- dihydroxyphenylalanine (6-L-[18F]FDOPA)...
|
|
WO/2023/247977A9 |
This invention relates to deuterated compounds useful in agriculture to treat diseases caused by oomycetes.
|
|
WO/2024/045292A1 |
The present invention relates to a method for catalytic industrial production of a deuterated pharmaceutical intermediate D by means of a combination of immobilized nickel and organic alkali. Reaction route conditions are mild, the conve...
|
|
WO/2024/049154A1 |
The present invention relates to a phenol compound substituted with a non-radioactive isotope and a use thereof, and more particularly, to a phenol compound in which some elements in biotin-phenol or desthiobiotin-phenol are substituted ...
|
|
WO/2024/037073A1 |
The present application belongs to the technical field of organic materials, and relates to a nitrogen-containing compound, an electronic element and an electronic device. The compound has a structure as shown in formula (1) below. The n...
|
|
WO/2024/036097A1 |
Provided herein are heteroaromatic macrocyclic ether compounds and isotopologues thereof, or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, and methods of treating, preventing or man...
|
|
WO/2024/023332A1 |
The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae (Ia, Ib, Ic) as well as to compounds suitable for use in radiopharmacy comprising such groups, wherein R1 and R2 are each a lin...
|
|
WO/2024/020077A1 |
Disclosed are compounds, compositions, and methods useful for imaging cells in a subject. In particular, the compound have the structure of Formula (I) is useful in the dislocsed imaging methods:
|
|
WO/2024/014325A1 |
An aromatic compound configured from a stable isotope, wherein two adjacent carbon atoms are 13C, the nuclear spin quantum number of the other atoms to which the two adjacent carbon atoms bond is 0, and a hydrogen atom that has a spin co...
|
|
WO/2024/008075A1 |
Provided are a preparation method for a liquid composition containing compound I and a use in myocardial perfusion PET imaging, the method comprising the following step: purifying a crude product containing the compound I by using high-p...
|
|
WO/2024/007464A1 |
Disclosed is a method for producing a deuterated compound with a tower device. By means of using an active deuterium reagent as a deuterium source, the content of deuterium in the product is continuously improved in the absence of a cata...
|
|
WO/2024/008073A1 |
The present application provides a liquid composition of compound I, a preparation method therefor, and an application thereof, wherein same is selected from one or more among vitamin C, sodium ascorbate, and gentisic acid. By optimizing...
|
|
WO/2024/006582A1 |
Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron- emitting mannitol analogue, [18F]fluoromanni...
|
|
WO/2024/001967A1 |
The present invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, and in particular, to an imidazonaphthyridine compound with affinity with a Tau protein, a method for preparing same, an...
|
|
WO/2023/249989A1 |
Described herein are solid forms of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3
-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]py
ridine-2-d, process of preparing the forms, pharmaceutical compositions, and me...
|
|
WO/2023/246829A1 |
A liquid composition comprising trans-2-(2-(5-(fluoro[ 18F])tridecyl)cyclopropyl)acetic acid, a preparation method therefor and use thereof in the preparation of a contrast agent for myocardial metabolic PET imaging. The liquid compositi...
|
|
WO/2023/247976A1 |
This invention relates to deuterated compounds useful in agriculture as herbicides.
|
|
WO/2023/246830A1 |
The present application provides a method for preparing a myocardial metabolism PET imaging agent, a liquid composition of trans-2-(2-(5-fluoro[18F]tridecyl)cyclopropyl)acetic acid (compound I for short), and use thereof, wherein a crude...
|
|
WO/2023/240849A1 |
Provided is a method for preparing a deuterated aromatic compound, the method comprising: taking an aromatic compound as a raw material, and under the protection of an inert atmosphere, subjecting same to a deuteration reaction in a solv...
|
|
WO/2023/240251A1 |
The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-am
ine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorp...
|
|
WO/2023/237091A1 |
The present application provides a device for producing a liquid composition of 2-tert-butyl-4-chloro-5-((3-((4-((2-(2-fluoro[18F]ethoxy)eth
oxy)methyl)-1H-1,2,3-triazole-1-yl)methyl)benzyl)oxy)pyridaz
ine-3(2H)-one (hereinafter referred...
|
|
WO/2023/235925A1 |
The present invention provides compounds of Formula (I), which have activity as inhibitors of MERTK. The present invention also provides radio-labelled compounds which may be used in diagnostic and imaging compositions. The present inven...
|
|
WO/2023/240205A1 |
The present disclosure provides deuterated compounds and their use as T-type calcium channel blockers in the treatment or prevention of various diseases or disorders associated with calcium T channels.
|
|
WO/2023/235734A1 |
The present disclosure provides deuterated compounds and their use as sodium channel blockers in the treatment or prevention of various diseases or disorders associated with sodium channels.
|
|
WO/2023/227996A1 |
The present invention relates to a process for synthesis of a deuterated compound. Most particularly, it relates to synthesis of a deuterated amine compounds of formula (l) and salts thereof. The said compound is an important key interme...
|
|
WO/2023/223050A1 |
The disclosures herein relate to methods of synthesising a compound of formula (1): (1) wherein PG, R2 and R3 are as defined herein, and the use of said methods in the manufacture of conjugates that bind to PSMA.
|
|
WO/2023/222559A1 |
The present invention relates to a process for preparing a deuterated organic compound, comprising the following steps: preparing a liquid composition comprising the organic compound, at least one heterogeneous metal catalyst, at least o...
|
